Randomized phase II study of weekly paclitaxel with or without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA HER2-negative breast cancer.

被引：2
作者：
Tamura, Kenji
Hashimoto, Jun
Tsuda, Hitoshi
Yoshida, Masayuki
Yamauchi, Hideko
Aogi, Kenjiro
Shimizu, Satoru
Iwata, Hiroji
Masuda, Norikazu
Yamamoto, Naohito
Inoue, Kenichi
Ohno, Shinji
Kuroi, Katsumasa
Sukigara, Tamie
Fujiwara, Yasuhiro
Andoh, Masashi
机构：
[1] Natl Canc Ctr, Dept Breast & Med Oncol, Tokyo, Japan
[2] Natl Canc Ctr, Dept Breast, Tokyo, Japan
[3] Natl Canc Ctr, Div Med Oncol, Tokyo, Japan
[4] Natl Def Med Coll, Dept Basic Pathol, Tokorozawa, Saitama 359, Japan
[5] Natl Canc Ctr, Dept Pathol & Labs, Tokyo, Japan
[6] St Lukes Int Hosp, Dept Breast Surg Oncol, Tokyo, Japan
[7] NHO Shikoku Canc Ctr, Dept Breast Oncol, Matsuyama, Ehime, Japan
[8] Kanagawa Canc Ctr, Dept Breast Oncol & Endocrine Surg, Yokohama, Kanagawa, Japan
[9] Aichi Canc Ctr, Dept Breast Oncol, Nagoya, Aichi 464, Japan
[10] NHO Osaka Natl Hosp, Dept Surg, Breast Oncol, Osaka, Japan
[11] Chiba Canc Ctr, Chiba 2608717, Japan
[12] Saitama Canc Ctr, Div Breast Oncol, Saitama, Japan
[13] Kyushu Natl Canc Ctr, Dept Clin Oncol, Fukuoka, Japan
[14] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Tokyo, Japan
[15] Natl Canc Ctr, Exploratory Oncol Res & Clin Trial Ctr, Tokyo, Japan
[16] Natl Canc Ctr, Tokyo, Japan
[17] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi 464, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.1017
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1017
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Neoadjuvant 5-fluorouracil, epirubicin and cyclophosphamide chemotherapy followed by docetaxel in refractory patients with locally advanced breast cancer
    Heller, W.
    Mazhar, D.
    Ward, R.
    Sinnett, H. D.
    Lowdell, C.
    Phillips, R.
    Shousha, S.
    Fayaz, A.
    Palmieri, C.
    Coombes, R. C.
    ONCOLOGY REPORTS, 2007, 17 (01) : 253 - 259
  • [42] Phase II trial of neoadjuvant chemotherapy with docetaxel followed by epirubicin in stage II/III breast cancer
    Ramaswamy, B
    Povoski, SP
    Rhoades, C
    Allen, J
    Hauger, M
    Young, D
    Burak, W
    Farrar, W
    Yee, L
    Kendra, K
    Somasundaram, S
    Orlowski, RZ
    Shapiro, CL
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 93 (01) : 67 - 74
  • [43] The efficacy and safety of 4 cycles of tri-weekly nanoparticle albumin-bound paclitaxel (nab-PTX) followed by 4 cycles of FEC (5-fluorouracil, epirubicin, cyclophosphamide) as neoadjuvant chemotherapy for patients with HER2-negative primary breast cancer - A multicenter phase II study (KBCSG-TR1213)
    Tanaka, K.
    Masuda, N.
    Matsunami, N.
    Takashima, T.
    Morimoto, T.
    Mizutani, M.
    Yoshidome, K.
    Yasojima, H.
    Morishima, H.
    Hata, K.
    Shiba, E.
    Tominaga, S.
    Nishi, T.
    Kamigaki, S.
    Yoshinami, T.
    Munakata, S.
    Takeda, M.
    Tsujimoto, M.
    Nakayama, T.
    EUROPEAN JOURNAL OF CANCER, 2016, 57 : S92 - S92
  • [44] Interim analysis of a phase II trial of cyclophosphamide, epirubicin and 5-fluorouracil (CEF) followed by docetaxel as preoperative chemotherapy for early stage breast carcinoma
    Hiroji Iwata
    Seigo Nakamura
    Masakazu Toi
    Eisei Shin
    Norikazu Masuda
    Shinji Ohno
    Yuichi Takatsuka
    Kazufumi Hisamatsu
    Kosuke Yamazaki
    Mikihiro Kusama
    Hiroshi Kaise
    Yasuyuki Sato
    Katsumasa Kuroi
    Futoshi Akiyama
    Hitoshi Tsuda
    Masafumi Kurosumi
    Breast Cancer, 2005, 12 (2) : 99 - 103
  • [45] A phase II study of neoadjuvant epirubicin/cyclophosphamide (EC) followed by weekly nanoparticle albumin-bound paclitaxel with or without trastuzumab for node-positive breast cancer
    Hirano, A.
    Hattori, A.
    Kamimura, M.
    Ogura, K.
    Kim, N.
    Setoguchi, Y.
    Okubo, F.
    Inoue, H.
    Jibiki, N.
    Miyamoto, R.
    Kinoshita, J.
    Kimura, K.
    Fujibayashi, M.
    Shimizu, T.
    CANCER RESEARCH, 2012, 72
  • [46] Phase II Trial of Neoadjuvant Chemotherapy with Docetaxel Followed by Epirubicin in Stage II/III Breast Cancer
    Bhuvaneswari Ramaswamy
    Steven P Povoski
    Chris Rhoades
    Joan Allen
    Marsha Hauger
    Donn Young
    William Burak
    William Farrar
    Lisa Yee
    Kari Kendra
    Sivagurunathan Somasundaram
    Robert Z Orlowski
    Charles L. Shapiro
    Breast Cancer Research and Treatment, 2005, 93 : 67 - 74
  • [47] A Randomized Phase II Study of Sequential Eribulin Versus Paclitaxel Followed by FAC/FEC as Neoadjuvant Therapy in Patients with Operable HER2-Negative Breast Cancer
    Lim, Bora
    Song, Juhee
    Ibrahim, Nuhad K.
    Koenig, Kimberly B.
    Chavez-MacGregor, Mariana
    Ensor, Joe E., Jr.
    Gomez, Jill Schwartz
    Krishnamurthy, Savitri
    Caudle, Abigail S.
    Shaitelman, Simona F.
    Whitman, Gary J.
    Valero, Vicente
    ONCOLOGIST, 2021, 26 (02) : E230 - E240
  • [48] Clinical outcomes of neoadjuvant chemotherapy for patients with breast cancer: Tri-weekly nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide: a retrospective observational study
    Shizuku, Masato
    Shibata, Masahiro
    Shimizu, Yoshimi
    Takeuchi, Dai
    Mizuno, Yutaka
    NAGOYA JOURNAL OF MEDICAL SCIENCE, 2020, 82 (03): : 457 - 467
  • [49] A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer
    Hiroshi Ishiguro
    Norikazu Masuda
    Nobuaki Sato
    Kenji Higaki
    Takashi Morimoto
    Yasuhiro Yanagita
    Makiko Mizutani
    Shoichiro Ohtani
    Koji Kaneko
    Tomomi Fujisawa
    Masato Takahashi
    Takayuki Kadoya
    Nobuki Matsunami
    Yutaka Yamamoto
    Shinji Ohno
    Toshimi Takano
    Satoshi Morita
    Sachiko Tanaka-Mizuno
    Masakazu Toi
    Breast Cancer Research and Treatment, 2020, 180 : 715 - 724
  • [50] PHASE-I TRIAL OF ADJUVANT CHEMOTHERAPY WITH CYCLOPHOSPHAMIDE, EPIRUBICIN AND 5-FLUOROURACIL (CEF) FOR STAGE-II BREAST-CANCER
    JONES, SE
    MENNEL, RG
    PETERS, GN
    WESTRICK, MA
    BROOKS, BD
    KNOX, SM
    MCGUFFEY, P
    INVESTIGATIONAL NEW DRUGS, 1988, 6 (03) : 195 - 198
12345